Sixteen startup teams pitched at the seventh annual — but first-ever virtual – Bayou Startup Showcase. Photo courtesy of OwlSpark and RED Labs

Even despite a global pandemic, two university-based summer startup accelerator programs were determined to continue on. And, that's exactly what they did.

University of Houston's RED Labs and Rice University's OwlSpark pivoted their summer program, which they put on collaboratively, to a virtual approach. On Thursday, August 6, the program's 16 startup teams pitched their projects at the seventh annual Bayou Startup Showcase.

Here are this year's Class 8 presentations:

EVA

Vascular access requires a medical team to use an ultrasound machine to help navigate a needle's precision during the procedure. However, 5 percent of procedures result in an inexact and painful outcome. OwlSpark company, EVA — which stands for Exact Vascular Access, has created a device that works with the ultrasound machine to endure navigation of the needle during the procedure.

CareSafe

Seven million people fall every year, but as great and helpful wearable devices are, they aren't foolproof. CareSafe, a RED Labs company, taps into home WiFi to visualize when a fall occurs and the company can even notify emergency contacts and emergency services.

Ai-Ris

People who live in underserved and rural areas don't have regular access to eye care — which means that these people are exposed to preventable eye diseases. Ai-Ris has created a portable, telemedicine-ready device that can help get these populations access to eye care.

Dividends360

Ninety million people invest in the stock market — and more than half of those investors are self directed and spending several hours a week on planning their investments. RED Labs company Dividends360 is a web-based platform to help the modern investor make his or her decisions in a more efficient way.

FirstGen Solutions

Expecting mothers can't take the majority of medications in the market because the effects of the chemicals on the unborn child is unknown, and testing is limited to costly, inaccurate, and highly regulated animal testing. FirstGen Solutions, an OwlSpark company, is producing a stem cell testing kit for pharmaceutical companies to use as an earlier and easier way to indicate potential risks a medicine could have.

nisa EFFECT

Women undergoing menopause have no control over their hot flashes, which can happen often, last up to 20 minutes, and be debilitating to daily activities. Nisa EFFECT has created a cooling bra so that the 80 percent of women who experience hot flashes during menopause can have a discrete way to cool down.

FreeFuse

Five hundred hours of video content is uploaded every minute, and the sheer oversaturation of the industry makes growing an audience extremely difficult for content producers. Interactive video platform FreeFuse, an OwlSpark company, wants to flip the script and allow content creators to see what its audient wants to see in terms of content.

Morpheus Health

Pharmaceutical companies don't make it easy to find out about side effects medicines can have on its users. Morpheus Health, an OwlSpark company, uses data and patient information to better customize and predict potential side effects a medicine can have. Morpheus's results don't replace prescriptions or doctor consultations, but instead allow the patient to take that information into the consultation room.

Phase Filter

​Changing the air filters is an easily forgotten chore that, if undone, can cause unnecessary air quality issues and a higher electricity bill for homeowners. Phase Filter has designed a self-scrolling air filter that's easy to install and only needs to be changed once a year,

Bloodhound

The OwlSpark and RED Labs summer programs are meant to help early-stage startups figure out their market need and determine whether or not their product is a viable business. The Bloodhound team explains how they came up with their idea for a software that helps detect bleed in surgeries, and then how they realized, after research and mentorship through the program, that it wasn't an idea worth pursuing. Doctors need more help with stopping bleeds than finding them.

Crew Trace Solutions

The Navy needs an upgrade to their accountability practice. That's where Crew Trace Solutions, an OwlSpark company run by two military veterans, comes in. The technology mirrors something like EZ-Tag where personnel onboard are tracked throughout the ship as they pass through sensors set up in doorways around the boat.

VAYL

Everyone dreads the discomfort and disappointment that usually comes with dental appointments. The oral hygiene tools on the market today aren't cutting it, says the VAYL team, a RED Labs company. VAYL has created a device that brushes the entire mouth in an optimal way for time and for cavity prevention.

MoodyCorium

Finding the right moisturizer is a costly and exhausting industry for women. MoodyCorium, an OwlSpark company, is working on a solution so that women can navigate the hundreds of products available on the market.

ElastEye

Half of the glaucoma patients could have had their disease prevented by better diagnostics — and that's exactly what ElastEye has developed. The RED Labs company has created a non-invasive, early detection device that determines the elasticity of the eye.

BitGrange

Supporting local farmers can be hard — it might raise the price of produce for consumers while orders tend to be smaller than farmers prefer. BItGrange, an OwlSpark company, created an e-commerce platform to allow consumers to go in on purchases together to create a win-win situation for both sides of the transaction.

dext

Simple daily tasks can be overwhelming to stroke survivors and the only solution is exercise and rehabilitation. Dext is a wearable tool to help take that exercise and rehab into a daily, easy to use setting.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.